Fennec Pharmaceuticals Inc — Cash Flow (NASDAQ:FENC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -15.6 M-14.22 M-18.06 M-17.14 M26.98 M-12.47 M -12.47 M Cash from investing activities —————— — Cash from financing activities 32.29 M4.98 M20.73 M6.64 M-13.62 M22.63 M 22.63 M Free cash flow -15.6 M-14.22 M-18.06 M-17.14 M26.98 M-12.47 M -12.47 M

News

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Fennec Pharmaceuticals (NASDAQ:FENC)

Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates

Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline

Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates

Certara, Inc. (CERT) Q4 Earnings Lag Estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)

City of Hope to study PEDMARK for hearing protection in testicular cancer

Fennec’s pediatric hearing protection drug shows positive results in Japan